D-0699-2021 Class II Ongoing
FDA drug recall D-0699-2021 was initiated by Pfizer Inc. on Jun 9, 2021 and is designated Class II. Reason for recall: CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit The recall status is ongoing. Affected quantity: 59,232 bottles.
Recall details
- Product Type
- Drugs
- Report Date
- Aug 11, 2021
- Initiation Date
- Jun 9, 2021
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 59,232 bottles
Product description
Chantix (varenicline) tablets, 0.5mg*, 56 Tablets, Rx Only, Distributed by Pfizer Labs, Division of Pfizer Inc., NY, NY 10017, Made in Ireland. NDC 0069-0468-56
Reason for recall
CGMP Deviations: Presence of the N-nitroso-varenicline impurity above FDA s acceptable interim acceptable intake limit
Distribution pattern
Nationwide
Code information
Lots 00019213, Exp 31 Jan 2022 & EC6994, Exp May 31, 2023
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0699-2021
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Pfizer Inc.? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.